Der Zusammenhang zwischen Prognose und Kieler Klassifikation der malignen Non-Hodgkin-Lymphome

Delbrück, H.; Weichert, H. C.; Schmitt, G.; Firusian, N; Wetter, O.

doi:10.1007/bf01477249

Cited by 12 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In continental Europe, use of the Rappaport classification remained scanty, and in the early seventies the Kiel classification, differentiating NHL by modern histo-and cytopathology and immunology, has been widely accepted by pathologists so that detailed studies of its clinical and prognostic implications became necessary. From 1973 to 1975, a retrospective investigation on 405 patients performed by the Kiel Lymphoma Study Group (KLSG) comprising 21 hospitals in West Germany and Austria (Brittinger et al, 1976Stacher et al, 1976;Bremer et al, 1977), and data published by other groups (Diihmke, 1976;Musshoff et al, 1976;Diihmke and Quack, 1977;Delbriick et al, 1978;Meuge et al, 1978) showed that the subdivision by the Kiel classification of NHL into two major histopathological groups (NHL of low-grade and high-grade malignancy) as well as into several lymphoma entities subsumed under these headings has prognostic relevance. Since, however, several questions such as the prognostic relevance of histopathological subclassifications of certain lymphoma entities or the initial stage of disease could not be answered by these investigations, in 1975 the Kiel Lymphoma Study Group initiated a prospective multicenter observation study.…”

Section: Introductionmentioning

confidence: 99%

Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group

Brittinger¹,

Bartels

Common³

et al. 1984

Hematological Oncology

203

View full text Add to dashboard Cite

Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas (NHL) was investigated in 1127 patients entering a prospective multicenter observation study. Survival of the 782 (69.4 per cent) patients with low-grade malignant NHL (lymphocytic lymphomas, predominantly B-CLL, LP immunocytoma, centrocytic lymphoma, centroblastic-centrocytic lymphoma) exceeded that of the 341 patients (30.2 per cent) with high-grade malignant NHL (centroblastic, immunoblastic, lymphoblastic lymphomas). Prognosis was best in centroblastic-centrocytic lymphoma and in B-CLL and least favorable in immunoblastic and lymphoblastic lymphomas. Survival of LP immunocytoma and centrocytic lymphoma patients was intermediate after 2 to 2.5 years of follow-up. Corresponding to histopathology, pattern of survival curves of low-grade malignant NHL (slow decline, no plateauing) differed from that of high-grade malignant NHL (rapid decline, subsequent plateauing). Prognosis of B-CLL was superior to that of LP immunocytoma. Stages I and II were more frequent in centroblastic-centrocytic lymphoma (21 per cent) than in LP immunocytoma (2.5 per cent) and centrocytic lymphoma (11 per cent). Ability of radiotherapy to induce stable complete remissions in stage III of centroblastic-centrocytic lymphoma indicates prolonged restriction of lymphoma to the lymphatic system. In immunoblastic and centroblastic lymphomas, stages I and II were diagnosed in 34 and 38 per cent of cases, respectively, but only in stage I/IE of centroblastic lymphoma prolonged remissions were achieved by radiotherapy. In advanced high-grade malignant NHL marked improvement of prognosis was solely possible by induction of complete remissions whereas in corresponding low-grade malignant lymphomas also partial remissions were prognostically relevant.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group

Brittinger¹,

Bartels

Common³

et al. 1984

Hematological Oncology

203

View full text Add to dashboard Cite

show abstract

“…Bemerkenswert Prognostisch gehört das Zentrozytom zu den niedrigmalignen Lym phomen (Tab. I), die eine signifikant günstigere Lebenserwartung haben als die hochmalignen [Bettini und Chelazzi, 1979;Bremer, 1977;Brittinger et al, 1976Brittinger et al, , 1978Delbrück et al, 1978;Diihmke, 1976;Mandardet al, 1977], Doch innerhalb der Gruppe mit niedriger Malignität kommt den Zentrozytomen möglicherweise eine Sonderstellung zu: Sie haben hier die schlechteste Pro gnose. Die mittlere Lebenserwartung beträgt 4 Jahre.…”

Section: Diskussionunclassified

“…Unsere Patientin kann dafür als Bei spiel dienen. Ansonsten sind die Zentrozytome im allgemeinen dadurch gekennzeichnet, dass sie ganz überwiegend zum Zeitpunkt der Diagnosestel lung generalisiert sind [Brittinger et al, 1976;Delbrück et al, 1978;Dühmke, 1976;König et al, 1979]. Aus diesem Grund wird das Zentrozytom auch als nichtleukämisches Gegenstück zur chronischen lymphatischen Leukämie be zeichnet [Becker, 1978].…”

Section: Diskussionunclassified

“…Grosse retrospektive Lymphomstudien existieren bisher nur aus dem hämatologisch-onkologischen Raum [Brittinger et al, 1976;Delbrück et al, 1978;Dühmke, 1976;Mandant et al, 1977], eine prospektive Studie ist im Gange [König et al, 1979]. Einzelbeobachtungen wie unser Fall weisen darauf hin, dass die primär kutanen B-Zell-Lymphome möglicherweise gegenüber den lymphonodalen Formen Besonderheiten aufweisen können.…”

Section: Diskussionunclassified

See 1 more Smart Citation

Primäres kutanes Zentrozytom: Diagnose, Verlauf und Therapie

Schultz-Ehrenburg¹,

Lämmer²

1981

Dermatology

View full text Add to dashboard Cite

A primary B-cell lymphoma of the skin is described, showing the clinical picture of a lymphadenosis cutis circumscripta. According to the Kiel classification, it has been classified as a centrocytic lymphoma (centrocytoma) belonging to the low-grade malignancy group. The centrocytoma is a newly defined type of lymphoma which is not identical with any earlier entity of lymphoreticular neoplasia. Although the centrocytoma is said to occur relatively often in the skin, the present case report seems to be the first clinical description of this variant.In our patient a solitary tumor of the face was found, which had slowly enlarged since 3½ years. No lymph node and no systemic involvement were detectable. With a telecobalt-60 treatment up to a total of 40 Gy (= 4,000 rad) a complete involution could be achieved without recurrence 6 months after radiotherapy had been finished. In contrast to the centrocytoma of lymphonodal origin, the primary cutaneous type may obviously remain localized for a long time with low tendency to progression.

show abstract

“…Several attempts have been made at classifying the heteroge nous group of non-Hodgkin lymphomas (NHL) [1], In Europe the Kiel classification has been widely used and has confirmed its relevance in several retrospective studies and one prospec tive trial [2][3][4][5][6][7]. New entities, e.g.…”

Section: Introductionmentioning

confidence: 99%

Long-Term Follow-Up of 1,654 Consecutive Non-Hodgkin Lymphoma Patients – Data from a Single Institution

Heinz¹,

Fortelny

Schneider

et al. 1995

Oncol Res Treat

View full text Add to dashboard Cite

Material and Methods: 1,654 non-Hodgkin lymphoma (NHL) patients defined according to the modified Kiel classification and treated at the 3rd Medical Depart -ment/Hanusch Hospital between 1.1.1975 and 31.12.1989 were analysed with regard to clinical presentation and outcome. Results: The median follow-up in our collective was 112 months. Survival of patients with B-cell NHL differed significantly between the subgroups of patients with low-grade and those with high-grade malignancy (p = 0.001). No such difference was seen in patients with T-cell lymphomas (p = 0.7). Symptoms at presentation and outcome were evaluated, and significant differences between the entities were found. Aggressive therapy failed to improve prognosis in patients with low-grade NHL, whereas early aggressive chemotherapy was found to ameliorate the outcome of high-grade NHL (p = 0.008). Improvement in low-grade NHL (p = 0.02) comparing the same periods might be attributable to early diagnosis in CLL (chronic lymphocytic leukaemia) and better supportive care. Conclusions: Late relapse, development of secondary high-grade NHL (1.4% in CLL, 9% in IC: immunocytoma, 11% in CBCC: centroblastic centrocytic lymphoma, and 40% in AILD: angioimmunoblastic lymphoma) as well as development of secondary non-lymphatic neoplasia (12% in our collective) emphasize the necessity of long-term observation in NHL patients.

show abstract

Der Zusammenhang zwischen Prognose und Kieler Klassifikation der malignen Non-Hodgkin-Lymphome

Cited by 12 publications

References 5 publications

Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group

Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group

Primäres kutanes Zentrozytom: Diagnose, Verlauf und Therapie

Long-Term Follow-Up of 1,654 Consecutive Non-Hodgkin Lymphoma Patients – Data from a Single Institution

Contact Info

Product

Resources

About